Cargando…

Association of Treatment With 5α-Reductase Inhibitors and Prostate Cancer Mortality Among Older Adults

This cohort study examines the association between use of 5α-reductase inhibitors and prostate cancer mortality among US Medicare beneficiaries.

Detalles Bibliográficos
Autores principales:	Kumar, Abhishek, Nalawade, Vinit, Riviere, Paul, Sarkar, Reith R., Parsons, J. Kellog, Murphy, James D., Rose, Brent S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Medical Association 2019
Materias:	Research Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6813580/ https://www.ncbi.nlm.nih.gov/pubmed/31626312 http://dx.doi.org/10.1001/jamanetworkopen.2019.13612

Ejemplares similares

Evaluation of the Use of Cancer Registry Data for Comparative Effectiveness Research
por: Kumar, Abhishek, et al.
Publicado: (2020)

Association of Prostate-Specific Antigen Velocity With Clinical Progression Among African American and Non-Hispanic White Men Treated for Low-Risk Prostate Cancer With Active Surveillance
por: Nelson, Tyler J., et al.
Publicado: (2021)

Is There a Link between 5α-Reductase Inhibitors and Hypoglycemia?
por: Jeong, Jin Woo, et al.
Publicado: (2021)

Prostate Cancer Mortality and Use of 5-Alpha Reductase Inhibitors
por: Foldes, Cara A., et al.
Publicado: (2020)

Current Status of 5α-Reductase Inhibitors in Prostate Disease Management
por: Kang, Dong Il, et al.
Publicado: (2013)

Computer aided screening of inhibitors to 5-α reductase type 2 for prostate cancer
por: Bhattacharjee, Biplab, et al.
Publicado: (2011)

Outcomes for Muscle-invasive Bladder Cancer with Radical Cystectomy or Trimodal Therapy in US Veterans
por: Kumar, Abhishek, et al.
Publicado: (2021)

Cardiovascular Outcomes of α-Blockers vs 5-α Reductase Inhibitors for Benign Prostatic Hyperplasia
por: Zhang, Jiandong, et al.
Publicado: (2023)

Use of 5α-reductase inhibitor and delay in prostate cancer diagnosis and treatment
por: Busato, Wilson F. S.
Publicado: (2020)

Low-Value Prostate-Specific Antigen Screening in Older Males
por: Kalavacherla, Sandhya, et al.
Publicado: (2023)

5-α reductase inhibitors, benign prostatic hyperplasia, and risk of male breast cancer
por: Robinson, David, et al.
Publicado: (2015)

Role of HMG-CoA reductase inhibitors with curative radiotherapy in men with prostate cancer
por: Solanki, Abhishek A, et al.
Publicado: (2011)

Medical therapy for clinical benign prostatic hyperplasia: α1 Antagonists, 5α reductase inhibitors and their combination
por: Shum, Cheuk Fan, et al.
Publicado: (2017)

5-α reductase inhibitors and prostate cancer prevention: where do we turn now?
por: Hamilton, Robert J, et al.
Publicado: (2011)

Association of 5-alpha-reductase inhibitor and prostate cancer incidence and mortality: a meta-analysis
por: Hu, Xu, et al.
Publicado: (2020)

Prognostic utility of pretreatment neutrophil-lymphocyte ratio in survival outcomes in localized non-small cell lung cancer patients treated with stereotactic body radiotherapy: Selection of an ideal clinical cutoff point
por: Kotha, Nikhil V., et al.
Publicado: (2021)

Black Holes in Higher Derivative Gravity
por: Stelle, Kellog
Publicado: (2019)

Effect of Shifting from Combination Therapy to Monotherapy of α-Blockers or 5α-Reductase Inhibitors on Prostate Volume and Symptoms in Patients with Benign Prostatic Hyperplasia
por: Kim, Hyoung Woo, et al.
Publicado: (2011)

Association between 5α-reductase inhibitors therapy and incidence, cancer-specific mortality, and progression of prostate cancer: evidence from a meta-analysis
por: Luo, Lian-Min, et al.
Publicado: (2019)

Pneumococcal Vaccination Utilization Among Hispanic Long-Term Colorectal Cancer Survivors: Cross-Sectional Assessment of Claims
por: Moran, Ryan J, et al.
Publicado: (2019)

Trends in Infertility Care Among Commercially Insured US Women During the COVID-19 Pandemic
por: Zhou, Beth, et al.
Publicado: (2021)

Peripheral zone prostate-specific antigen density: an effective parameter for prostate cancer prediction in men receiving 5α-reductase inhibitors
por: Koo, Kyo Chul, et al.
Publicado: (2013)

Prostate-Specific Antigen Kinetics Following 5α-Reductase Inhibitor Treatment May Be a Useful Indicator for Repeat Prostate Biopsy
por: Heo, Ji Eun, et al.
Publicado: (2018)

Role of 5 alpha-reductase inhibitors in the management of prostate cancer
por: Hudak, Steven J, et al.
Publicado: (2006)

5-alpha reductase inhibitors use in prostatic disease and beyond
por: Chislett, Bodie, et al.
Publicado: (2023)

Is DHT Production by 5α-Reductase Friend or Foe in Prostate Cancer?
por: Kosaka, Takeo, et al.
Publicado: (2014)

5α-reductase inhibitors impact prognosis of urothelial carcinoma
por: Wang, Chien-Sheng, et al.
Publicado: (2020)

Association of 5α-Reductase Inhibitors With Dementia, Depression, and Suicide
por: Garcia-Argibay, Miguel, et al.
Publicado: (2022)

Association of Physician Referrals with Timely Cancer Care Using Tumor Registry and Claims Data
por: Schiaffino, Melody K., et al.
Publicado: (2022)

5-alpha reductase inhibitors and MRI prostates: actively reducing prostate sizes and ambiguity
por: Wang, Ziting, et al.
Publicado: (2023)

Androgen Regulation of 5α-Reductase Isoenzymes in Prostate Cancer: Implications for Prostate Cancer Prevention
por: Li, Jin, et al.
Publicado: (2011)

A Dual 5α-Reductase Inhibitor Dutasteride Caused Reductions in Vascular Density and Area in Benign Prostatic Hyperplasia
por: Zaitsu, Masayoshi, et al.
Publicado: (2013)

The Dark Side of 5α-Reductase Inhibitors' Therapy: Sexual Dysfunction, High Gleason Grade Prostate Cancer and Depression
por: Traish, Abdulmaged M., et al.
Publicado: (2014)

Potential impact of combined inhibition of 3α-oxidoreductases and 5α-reductases on prostate cancer
por: Fiandalo, Michael V., et al.
Publicado: (2019)

The impact of finasteride and dutasteride treatments on proliferation, apoptosis, androgen receptor, 5α-reductase 1 and 5α-reductase 2 in TRAMP mouse prostates
por: Opoku-Acheampong, Alexander B., et al.
Publicado: (2017)

The use of 5-alpha reductase inhibitors in the treatment of benign prostatic hyperplasia
por: Kim, Eric H., et al.
Publicado: (2018)

Long-term Combination Therapy With α-Blockers and 5α-Reductase Inhibitors in Benign Prostatic Hyperplasia: Patient Adherence and Causes of Withdrawal From Medication
por: Ong, Hueih Ling, et al.
Publicado: (2016)

Prostate Cancers Detected During 5α-Reductase Inhibitor Use Are Smaller, De-Differentiated, But Confined when Compared To Controls
por: Lee, Fred, et al.
Publicado: (2012)

α-Blocker Monotherapy and α-Blocker Plus 5-Alpha-Reductase Inhibitor Combination Treatment in Benign Prostatic Hyperplasia; 10 Years' Long-Term Results
por: Shin, Teak Jun, et al.
Publicado: (2012)

α1-Blockers and 5α-Reductase Inhibitors Are the Most Recommended Drugs in Treating Benign Prostatic Hyperplasia: An Evidence-Based Evaluation of Clinical Practice Guidelines
por: Xu, Xiao-Feng, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_0uvd5fa48sehqlv3h4thbk4h1q